{"filing":{"accession_number":"0001171843-26-006010","cik":"0001627281","ticker":"CLLS","company_name":"Cellectis S.A.","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"f6k_091326.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1627281/000117184326006010/f6k_091326.htm"},"events":[{"id":33057,"run_id":30384,"accession_number":"0001171843-26-006010","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Cellectis announced a strategic transformation approved by its board on September 11, 2026, to pivot from cell therapy (lasme-cel and eti-cel) to in vivo gene editing, with two lead programs (.HEAL-101 and .HEAL-201) advancing toward Phase 1 trials. The company is exiting lasme-cel and eti-cel development, realigning its operating model, and extending cash runway to H2 2028. This is a material strategic and operational restructuring affecting the company's pipeline, resource allocation, and financial trajectory, but does not fit the specific categories of M\u0026A, workforce reduction (though implied), or other named event types—it is a comprehensive strategic pivot that is clearly operational in nature.","company_name":"Cellectis S.A.","ticker":"CLLS","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36389,"accession_number":"0001171843-26-006010","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cellectis announced a strategic transformation approved by its board on September 11, 2026, to pivot from cell therapy (lasme-cel and eti-cel) to in vivo gene editing, with two lead programs (.HEAL-101 and .HEAL-201) advancing toward Phase 1 trials. The company is exiting lasme-cel and eti-cel development, realigning its operating model, and extending cash runway to H2 2028. This is a material strategic and operational restructuring affecting the company's pipeline, resource allocation, and financial trajectory, but does not fit the specific categories of M\u0026A, workforce reduction (though implied), or other named event types—it is a comprehensive strategic pivot that is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:45.921757+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36389,"accession_number":"0001171843-26-006010","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Cellectis announced a strategic transformation approved by its board on September 11, 2026, to pivot from cell therapy (lasme-cel and eti-cel) to in vivo gene editing, with two lead programs (.HEAL-101 and .HEAL-201) advancing toward Phase 1 trials. The company is exiting lasme-cel and eti-cel development, realigning its operating model, and extending cash runway to H2 2028. This is a material strategic and operational restructuring affecting the company's pipeline, resource allocation, and financial trajectory, but does not fit the specific categories of M\u0026A, workforce reduction (though implied), or other named event types—it is a comprehensive strategic pivot that is clearly operational in nature.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T10:04:45.921757+00:00","company_name":"Cellectis S.A.","ticker":"CLLS","filing_date":"2026-09-14"}]}